A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease

Journal of Ocular Pharmacology and Therapeutics, Ahead of Print.

Source: Journal of Ocular Pharmacology and Therapeutics - January 15, 2021 Category: Opthalmology Authors: David Clark John Sheppard Todd C. Brady Source Type: research